Switch theme
Sign up to access all valuation multiples
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
2014
41
LTM Revenue $8.6M
Last FY EBITDA -$37.5M
$57.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cue Biopharma has a last 12-month revenue (LTM) of $8.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cue Biopharma achieved revenue of $9.3M and an EBITDA of -$37.5M.
Cue Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cue Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $8.6M | XXX | $9.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$37.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -404% | XXX | XXX | XXX |
| EBIT | -$40.1M | XXX | -$41.6M | XXX | XXX | XXX |
| EBIT Margin | -465% | XXX | -448% | XXX | XXX | XXX |
| Net Profit | -$39.6M | XXX | -$40.7M | XXX | XXX | XXX |
| Net Margin | -459% | XXX | -438% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Cue Biopharma's stock price is $1.
Cue Biopharma has current market cap of $63.3M, and EV of $57.3M.
See Cue Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57.3M | $63.3M | XXX | XXX | XXX | XXX | $-0.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Cue Biopharma has market cap of $63.3M and EV of $57.3M.
Cue Biopharma's trades at 6.2x EV/Revenue multiple, and -1.5x EV/EBITDA.
Equity research analysts estimate Cue Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cue Biopharma has a P/E ratio of -1.6x.
See valuation multiples for Cue Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $63.3M | XXX | $63.3M | XXX | XXX | XXX |
| EV (current) | $57.3M | XXX | $57.3M | XXX | XXX | XXX |
| EV/Revenue | 6.6x | XXX | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.5x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCue Biopharma's last 12 month revenue growth is 6%
Cue Biopharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.2M for the same period.
Cue Biopharma's rule of 40 is -833% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cue Biopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cue Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -404% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -833% | XXX | -398% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 391% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 548% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cue Biopharma acquired XXX companies to date.
Last acquisition by Cue Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Cue Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cue Biopharma founded? | Cue Biopharma was founded in 2014. |
| Where is Cue Biopharma headquartered? | Cue Biopharma is headquartered in United States of America. |
| How many employees does Cue Biopharma have? | As of today, Cue Biopharma has 41 employees. |
| Who is the CEO of Cue Biopharma? | Cue Biopharma's CEO is Mr. Daniel R. Passeri. |
| Is Cue Biopharma publicy listed? | Yes, Cue Biopharma is a public company listed on NAS. |
| What is the stock symbol of Cue Biopharma? | Cue Biopharma trades under CUE ticker. |
| When did Cue Biopharma go public? | Cue Biopharma went public in 2018. |
| Who are competitors of Cue Biopharma? | Similar companies to Cue Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cue Biopharma? | Cue Biopharma's current market cap is $63.3M |
| What is the current revenue of Cue Biopharma? | Cue Biopharma's last 12 months revenue is $8.6M. |
| What is the current revenue growth of Cue Biopharma? | Cue Biopharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Cue Biopharma? | Current revenue multiple of Cue Biopharma is 6.6x. |
| Is Cue Biopharma profitable? | Yes, Cue Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
